Investment & transaction experience

Capital judgment
across the cycle.

Direct investing, structured credit, biotechnology, special situations, litigation finance, and operating finance—from origination and diligence through monitoring, restructuring, and exit.

Career scale

Experience measured in decisions, not labels.

$800M+Investments and loans evaluated, structured, or managed

50+Recorded direct-financing transactions

$225M+Recorded funded amounts, excluding equity-line throughput

$250M+Healthcare-focused leveraged-loan portfolio

150+Leveraged-credit underwritings

250+Investment-committee presentations

These figures describe different, potentially overlapping views of the career record and are not additive.

Experience by platform

A consistent process across different markets.

Public & Private Investment Firm

Direct investing & special situations · 1998–2010

Managed approximately $550 million across public equities, PIPEs, private credit, venture capital, convertibles, and special situations.
Surviving records show 52 financings and more than $225 million of stated funded amounts, excluding structured equity-line throughput.
Worked directly with issuers on modeling, valuation, diligence, security design, negotiation, execution, syndication, trading, and restructuring.
Named examples include VaxGen, ChromaVision, Entelos, and a proposed Cerus senior-secured note and warrant financing.

Alternative Asset Manager

Structured & healthcare credit · 2011–2016

Developed credit-rating methods and surveillance processes supporting more than 500 regional-bank credits.
Managed approximately $250 million of healthcare-focused investments across hospitals, pharmaceuticals, diagnostics, nursing facilities, and specialty providers.
Produced more than 250 investment-committee presentations covering investment, valuation, sizing, risk, monitoring, and exit.

Biotechnology Investment Partnership

Biotechnology & leveraged credit · 2016–2019

Managed biotechnology and leveraged-credit strategies in partnership with the firm’s founder.
Led scientific, clinical, commercial, and financial diligence across biotechnology and pharmaceutical opportunities.
Co-managed a biotechnology portfolio that nearly tripled over a two-year period through research and portfolio construction.

Middle-Market Direct Lender

Credit monitoring & valuation · 2019–2020

Senior member of the valuation and credit-monitoring team for technology, software, and healthcare credits.
Conducted fundamental credit analysis, portfolio surveillance, and valuation review across private borrowers.

Specialty / Litigation Finance Advisory

Portfolio advisory · 2021–present

Senior adviser to approximately $125 million of litigation-finance assets.
Work spans portfolio construction, valuation, acquisition strategy, diligence, risk management, investor communications, capital formation, audits, and reporting.
Named strategies include Camp Lejeune and AFFF/PFAS; counterparties and current marks remain confidential.

Current Operating Finance

Fractional CFO & executive leadership · 2025–present

Financial leadership for an integrated marketing and technology platform serving legal, healthcare, and mass-tort industries.
Advises ownership on strategy, capital allocation, budgeting, forecasting, KPIs, financing alternatives, organization, and profitability.

Selected transactions and strategies

Representative evidence.

Strategy	Transaction / asset	Platform	Role
Biotechnology PIPE	VaxGen	Direct-investment platform	$15 million lead participation in a $20 million structured financing; active monitoring through changing clinical and corporate facts.
Medical-technology PIPE	ChromaVision	Direct-investment platform	$5 million lead position in a $12.5 million preferred-and-warrant financing; trading, hedging, and restructuring.
Healthcare technology credit	Entelos	Special-situations platform	$5 million senior-secured convertible debenture position; asset, covenant, and restructuring analysis.
Structured private credit	Cerus Corporation	Special-situations platform	Developed a proposed senior-secured note, warrant package, covenants, and follow-on option; detailed economics remain confidential.
Mass-tort case acquisition	Camp Lejeune	Advisory platform	Portfolio acquisition, financing, valuation, risk monitoring, and investor communication.
Environmental personal injury	AFFF / PFAS	Advisory platform	Inventory sourcing, exposure and disease underwriting, vendor assessment, and portfolio valuation.
Structured credit	Regional-bank TruPS / CDOs	Alternative asset manager	Underlying-bank analysis, cash-flow and recovery frameworks, ratings, and surveillance.
Healthcare leveraged loans	Anonymized portfolio	Alternative asset manager	Underwriting, monitoring, valuation, investment committee, sizing, and exit decisions.

Aggregate figures describe different and potentially overlapping scopes. Structured equity-line throughput is excluded from the recorded funded total. Certain borrower, client, counterparty, and transaction details are omitted for confidentiality.

Capital judgmentacross the cycle.